S Gastrointestinal And Liver Disease 12th Edition !full! Jun 2026

In the complex and ever-changing world of gastroenterology, this is the one resource you cannot afford to be without.

: Fully integrates the new nomenclature for Metabolic Dysfunction-Associated Steatotic Liver Disease ( MASLD ), replacing the historical term NAFLD. s gastrointestinal and liver disease 12th edition

The text is filled with clear, actionable algorithms that aid in clinical decision-making. In the complex and ever-changing world of gastroenterology,

Hundreds of new full-color endoscopic photos, histopathological stains, and cross-sectional radiographic images assist in real-world diagnostic correlation. | | Pancreatic Cystic Lesions | Revised Sendai

| | Key Update in the 12th Edition | | :--- | :--- | | Eosinophilic Esophagitis (EoE) | Updated diagnostic criteria (EoE Histology Scoring System); new therapies including budesonide oral suspension and dupilumab. | | Inflammatory Bowel Disease (IBD) | Comparative efficacy of advanced therapies (JAK inhibitors, anti-IL23, S1P modulators); role of intestinal ultrasound for monitoring. | | Pancreatic Cystic Lesions | Revised Sendai and Fukuoka guidelines; role of molecular markers (KRAS/GNAS mutations) in cyst fluid. | | Celiac Disease | Novel serologic markers (deamidated gliadin peptides); management of non-responsive celiac disease; potential for lanrazenotide. | | Colorectal Cancer Screening | USPSTF updated age to 45; role of multitarget stool DNA (Cologuard) and blood-based tests (Shield); post-polypectomy surveillance intervals. |

: Serving as the definitive preparatory curriculum for board certification examinations.